Biodistribution of the boron carriers boronophenylalanine (BPA) and/or decahydrodecaborate (GB-10) for Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases.

Abstract

BNCT was proposed for the treatment of diffuse, non-resectable tumors in the lung. We performed boron biodistribution studies with 5 administration protocols employing the boron carriers BPA and/or GB-10 in an experimental model of disseminated lung metastases in rats. All 5 protocols were non-toxic and showed preferential tumor boron uptake versus lung. Absolute tumor boron concentration values were therapeutically useful (25-76ppm) for 3 protocols. Dosimetric calculations indicate that BNCT at RA-3 would be potentially therapeutic without exceeding radiotolerance in the lung.

• Authors: V A Trivillin, M A Garabalino, L L Colombo, S J González, R O Farías, A Monti Hughes, E C C Pozzi, S Bortolussi, S Altieri, M E Itoiz, R F Aromando, D W Nigg, A E Schwint
• Journal: Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine (Appl Radiat Isot) Vol. 88 Pg. 94-8 (Jun 2014) ISSN: 1872-9800 [Electronic] England
• PMID: 24360862 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2013 Published by Elsevier Ltd.

Chemical References

• Boron Compounds
• Drug Combinations
• decahydrodecaborate
• Phenylalanine
• 4-boronophenylalanine

Topics

• Animals
• Boron Compounds (administration & dosage, pharmacokinetics)
• Boron Neutron Capture Therapy (methods)
• Cell Line, Tumor
• Drug Combinations
• Lung Neoplasms (metabolism, radiotherapy, secondary)
• Metabolic Clearance Rate
• Organ Specificity
• Phenylalanine (administration & dosage, analogs & derivatives, pharmacokinetics)
• Radiotherapy Dosage
• Rats
• Tissue Distribution